Stephen V Liu: Reassuring Pooled Analysis of Grade 1 Pneumonitis in Patients Retreated with Trastuzumab Deruxtecan
Stephen V Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X about recent paper by H.S. Rugo et al., published in Annals of Oncology:
“Reassuring pooled analysis of 45 patients who had grade 1 pneumonitis from trastuzumab deruxtecan (T-DXd) and were retreated, Annals of Oncology.
Median duration of therapy was 85d, 18% treated for ≥1 year, 33% had reoccurrence of ILD/pneumonitis, all grade 1/2.”
Title: Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Journal: Annals of Oncology
Authors: H.S. Rugo, E. Tokunaga, H. Iwata, V. Petry, E.F. Smit, Y. Goto, D.-W. Kim, K. Shitara, J. Franklin Gruden, S. Modi, J. Cortés, I. Krop, P.A. Jänne, Y. Cheng, C. Taitt, F.-C. Cheng, C.A. Powell
More posts featuring Stephen V Liu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023